Bayer – Group report and key figures
A report presented through summary slides of group's operations
Detailed history of financial performances between 2020 and 2024
An overview of the group's major business strategies
A medium-term outlook for opportunities and threats
650 €
WHAT IS THE GROUPS' FINANCIAL SITUATION ?
The financial indicators presented in this report include: consolidated revenue, consolidated EBIT and EBIT ratio, consolidated net profit and net profit rate, R&D expenditure and ratio, sales by segment and by region, profitability, liquidity and solvency ratios, free cash flow and capital expenditure.
WHAT ARE THE GROUP'S STRATEGIC PRIORITIES ?
Accelerate pharmaceutical pipeline transition
Mitigate legal risks while transitioning Crop Science portfolio
Restructure operations via Dynamic Shared Ownership
WHAT ARE THE GROUP'S STRENGTHS AND WEAKNESSES ?
Through a SWOT analysis, this report also provides an overview of the group's strengths (deep production capabilities and customer networks, etc.) and weaknesses (persistent legal overhang related to glyphosate litigation, with €5.7bn in provisions as of 2024, etc.).
Detailed plan
Presentation
Segments
SWOT
Related reports
ACCESS THE REPORT
